» Articles » PMID: 25184003

Targeted Gene Suppression by Inducing De Novo DNA Methylation in the Gene Promoter

Overview
Publisher Biomed Central
Specialties Biochemistry
Genetics
Date 2014 Sep 4
PMID 25184003
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Targeted gene silencing is an important approach in both drug development and basic research. However, the selection of a potent suppressor has become a significant hurdle to implementing maximal gene inhibition for this approach. We attempted to construct a 'super suppressor' by combining the activities of two suppressors that function through distinct epigenetic mechanisms.

Results: Gene targeting vectors were constructed by fusing a GAL4 DNA-binding domain with a epigenetic suppressor, including CpG DNA methylase Sss1, histone H3 lysine 27 methylase vSET domain, and Kruppel-associated suppression box (KRAB). We found that both Sss1 and KRAB suppressors significantly inhibited the expression of luciferase and copGFP reporter genes. However, the histone H3 lysine 27 methylase vSET did not show significant suppression in this system. Constructs containing both Sss1 and KRAB showed better inhibition than either one alone. In addition, we show that KRAB suppressed gene expression by altering the histone code, but not DNA methylation in the gene promoter. Sss1, on the other hand, not only induced de novo DNA methylation and recruited Heterochromatin Protein 1 (HP1a), but also increased H3K27 and H3K9 methylation in the promoter.

Conclusions: Epigenetic studies can provide useful data for the selection of suppressors in constructing therapeutic vectors for targeted gene silencing.

Citing Articles

Human cytomegalovirus hijacks host stress response fueling replication stress and genome instability.

Merchut-Maya J, Bartek Jr J, Bartkova J, Galanos P, Pantalone M, Lee M Cell Death Differ. 2022; 29(8):1639-1653.

PMID: 35194187 PMC: 9346009. DOI: 10.1038/s41418-022-00953-w.


Pluripotency exit is guided by the Peln1-mediated disruption of intrachromosomal architecture.

Wang Y, Jia L, Wang C, Du Z, Zhang S, Zhou L J Cell Biol. 2022; 221(4).

PMID: 35171230 PMC: 8855478. DOI: 10.1083/jcb.202009134.


DNA hypermethylation of the promoter attenuates forkhead box protein 3 (FOXP3) expression in hepatocellular carcinoma cells.

Lin Z, Liu X, Liu X, Liu J Transl Cancer Res. 2022; 8(5):2024-2031.

PMID: 35116951 PMC: 8799006. DOI: 10.21037/tcr.2019.09.09.


KRAB-Induced Heterochromatin Effectively Silences Gene Expression in Somatic Cells and is Resilient to TGFβ1 Activation.

Gjaltema R, Goubert D, Huisman C, Pilar Garcia Tobilla C, Koncz M, Jellema P Int J Mol Sci. 2020; 21(10).

PMID: 32455614 PMC: 7279273. DOI: 10.3390/ijms21103634.


Oplr16 serves as a novel chromatin factor to control stem cell fate by modulating pluripotency-specific chromosomal looping and TET2-mediated DNA demethylation.

Jia L, Wang Y, Wang C, Du Z, Zhang S, Wen X Nucleic Acids Res. 2020; 48(7):3935-3948.

PMID: 32055844 PMC: 7144914. DOI: 10.1093/nar/gkaa097.


References
1.
Towbin B, Gonzalez-Aguilera C, Sack R, Gaidatzis D, Kalck V, Meister P . Step-wise methylation of histone H3K9 positions heterochromatin at the nuclear periphery. Cell. 2012; 150(5):934-47. DOI: 10.1016/j.cell.2012.06.051. View

2.
Klug M, Rehli M . Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector. Epigenetics. 2007; 1(3):127-30. DOI: 10.4161/epi.1.3.3327. View

3.
Zhang S, Zhong B, Chen M, Yang L, Yang G, Li Y . Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells. Int J Cancer. 2013; 134(7):1583-94. DOI: 10.1002/ijc.28487. View

4.
Matsuda E, Agata Y, Sugai M, Katakai T, Gonda H, Shimizu A . Targeting of Krüppel-associated box-containing zinc finger proteins to centromeric heterochromatin. Implication for the gene silencing mechanisms. J Biol Chem. 2001; 276(17):14222-9. DOI: 10.1074/jbc.M010663200. View

5.
Yao X, Hu J, Daniels M, Yien H, Lu H, Sharan H . A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res. 2003; 9(7):2719-26. View